2 results
Approved WMOPending
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…
Approved WMORecruiting
Primary: To characterize safety and tolerability of TNO155 and identify a recommended dose and regimen for future studies in adult patients with advanced solid tumors. And a recommended dose of TNO155 in combination with nazartinib in patients with…